If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New spin-out company

26 Nov 2014 07:00

RNS Number : 9910X
Frontier IP Group plc
26 November 2014
 



 

 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Company")

 

New Spin-out Company - Cambridge Simulation Solutions Limited

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that it has received a stake in Cambridge Simulation Solutions Ltd ("Cambridge Simulation"), a spin-out company from the Department of Chemical Engineering and Biotechnology at the University of Cambridge (the "Department").

Frontier IP has entered into an agreement with Cambridge Simulation in which it provides advisory and business development services in return for which it has received a 40% equity stake in the new spin-out. Cambridge Simulation has been formed to exploit the technology developed by Dr. Vassilios Vassiliadis, a Senior Lecturer at the Department. Dr. Vassiliadis has developed a method to simulate and control complex chemical processes and Frontier IP's role will be to support the licensing and commercialisation of this technology, which potentially has a wide range of commercial applications in industry, including the food and pharmaceutical sectors.

The Department of Chemical Engineering and Biotechnology at the University of Cambridge is a leading global research department, with Chemical Engineering ranked the best in the world outside the US and 4th in the world including the US (QS World University Rankings by Subject 2014). Working effectively with industry is a core strength of the Department, as is progressing novel technologies through spinout companies and licensing agreements to ultimate launch of marketed products.

Neil Crabb, Chief Executive of Frontier IP, said,

"This collaboration with Dr. Vassilios Vassiliadis represents an exciting new opportunity for Frontier IP. We have in-depth experience in commercialising IP and we look forward to working with Dr. Vassiliadis and the Department of Chemical Engineering and Biotechnology at the University of Cambridge to maximise the potential of the existing and the upcoming IP."

Dr. Vassiliadis, said,

"The aim of Cambridge Simulation is to produce a rapid integrator engine suitable for a range of applications and industries, including Chemical Engineering, Biotechnology, Biomedical, Pharmaceuticals, Aerospace and Microelectronics. I'm delighted to be entering into this collaboration with Frontier IP."

Professor Nigel Slater at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, said,

"The Department of Chemical Engineering and Biotechnology at the University of Cambridge fuses leading-edge biotechnology research with chemical engineering skills within an ethos of commercial awareness and exploitation. Broadly, our research strategy targets sustainable reaction engineering, product engineering and healthcare and the Department's activities are structured to provide novel solutions to these challenges. I welcome the launch of this company, as an example of the Department's innovative spirit in tackling the issues of our time."

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Jon Levinson / Lucy Williams

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

 

 

Notes to Editor:

 

Frontier IP Group plc ("Frontier IP") specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes. www.frontierip.co.uk.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMMZMNKLGDZM
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.